Pegylated interferon alfa-2a has demonstrated comparable or superior efficacy and a similar safety profile to conventional IFN-α in various disease settings, including chronic hepatitis C [14]. This evidence concerns the gene IFNA1 and chronic hepatitis C virus infection.